RAN-QUINAPRIL TABLET

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE)

Disponível em:

RANBAXY PHARMACEUTICALS CANADA INC.

Código ATC:

C09AA06

DCI (Denominação Comum Internacional):

QUINAPRIL

Dosagem:

20MG

Forma farmacêutica:

TABLET

Composição:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20MG

Via de administração:

ORAL

Unidades em pacote:

30/1000

Tipo de prescrição:

Prescription

Área terapêutica:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Resumo do produto:

Active ingredient group (AIG) number: 0123206003; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2014-10-17

Características técnicas

_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................